Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Sales and Marketing
11. Eli Lilly
Cosentyx woes, generics weakness cast cloud on Novartis earnings
Thursday, April 19, 2018
Novartis investors' discontent with first-quarter results shows how much they're expecting of new CEO Vas Narasimhan.
Latest field facing a payer squeeze? New, better psoriasis meds
Wednesday, February 21, 2018
Psoriasis treatments are getting more effective. But that doesn’t mean patients have easy access to a new-and-improved crop of blockbuster hopefuls.
Lilly chases Taltz-Cosentyx tilt with new spondylitis data
Wednesday, February 14, 2018
In December, Eli Lilly’s Taltz got a go-ahead to take on rival Cosentyx from Novartis in its second indication. But it’s not stopping there.
Lilly's ED med Cialis sees sales suffer in wake of Viagra generics
Wednesday, January 31, 2018
Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018 guidance.
Pfizer takes on Novartis, Lilly with new Xeljanz nod
Friday, December 15, 2017
For the second straight week, there’s a new psoriatic arthritis drug on the block.
AbbVie aims for best-in-class with psoriasis drug risankizumab
Wednesday, December 6, 2017
Recent years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class med may still be on its way, one analyst says.
Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis
Monday, December 4, 2017
Eli Lilly’s Taltz officially has a new arena to challenge Novartis’ Cosentyx.
Novartis looks past psoriasis for big Cosentyx growth frontier
Tuesday, November 14, 2017
Novartis’ Cosentyx currently leads a crop of immunology meds from a who’s who of Big Pharma. And the company intends to keep it that way.
Humira back on top of TV ad spend, ahead of Lyrica and Victoza
Beth Snyder Bulik
Monday, November 6, 2017
After a rare decline last month, AbbVie's Humira reclaimed its title as top advertised drug on TV with more than $40 million in spending.